• Tirzepatide


  • CasNo:2023788-19-2
  • Purity:99%

Product Details;

CasNo: 2023788-19-2

Molecular Formula: C225H348N48O68

Buy High Grade 2023788-19-2, Offer with Reasonable Price

  • Molecular Formula:C225H348N48O68
  • Molecular Weight:4813

Tirzepatide (Cas 2023788-19-2) Usage


In November 2023, the FDA approved tirzepatide for weight loss in individuals without diabetes under the brand name Zepbound. It is the first medication in its class and is administered as a once-weekly injection.


Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes and for weight loss. It is administered through subcutaneous injection and is sold under the brand name Mounjaro, among others. It works by impacting the body's insulin levels, blood glucose (sugar) production, and hunger hormones.


2023788-19-2 Relevant articles

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Thinzar Min & Stephen C. Bain

, Diabetes Therapy, Volume 12, pages 143–157, (2021)

Tirzepatide is a novel dual GIP/GLP-1 receptor agonist formulated as a synthetic peptide containing 39 amino acids, based on the native GIP sequence. Pre-clinical trials and phase 1 and 2 clinical trials indicate that tirzepatide has potent glucose lowering and weight loss with adverse effects comparable to those of established GLP-1 receptor agonists.

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Prof Bernhard Ludvik, MD Prof Francesco Giorgino, MD Prof Esteban Jódar, MD Juan P Frias, MD Laura Fernández Landó, MD Katelyn Brown, PharmD

, The Lancet, 2021

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to assess the efficacy and safety of tirzepatide versus titrated insulin degludec in people with type 2 diabetes inadequately controlled by metformin with or without SGLT2 inhibitors.